Search
Research
Standardization of Epidemiological Surveillance of Group A Streptococcal ImpetigoImpetigo is a highly contagious bacterial infection of the superficial layer of skin. Impetigo is caused by group A Streptococcus (Strep A) and Staphylococcus aureus, alone or in combination, with the former predominating in many tropical climates. Strep A impetigo occurs mainly in early childhood, and the burden varies worldwide. It is an acute, self-limited disease, but many children experience frequent recurrences that make it a chronic illness in some endemic settings.
Research
Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021Invasive aspergillosis (IA) in haematology/oncology patients presents as primary infection or breakthrough infection, which can become refractory to antifungal treatment and has a high associated mortality. Other emerging patient risk groups include patients in the intensive care setting with severe respiratory viral infections, including COVID-19.
Research
Introduction to the updated Australasian consensus guidelines for the management of invasive fungal disease and use of antifungal agents in the haematology/oncology setting, 2021This article introduces the fourth update of the Australian and New Zealand consensus guidelines for the management of invasive fungal disease and use of antifungal agents in the haematology/oncology setting. These guidelines are comprised of nine articles as presented in this special issue of the Internal Medicine Journal. This introductory chapter outlines the rationale for the current update and the steps taken to ensure implementability in local settings.
Research
Clinical experience with SUBA-itraconazole at a tertiary paediatric hospitalItraconazole remains a first-line antifungal agent for certain fungal infections in children, including allergic bronchopulmonary aspergillosis (ABPA) and sporotrichosis, but poor attainment of therapeutic drug levels is frequently observed with available oral formulations. A formulation of 'SUper BioAvailability itraconazole' (SUBA-itraconazole; Lozanoc®) has been developed, with adult studies demonstrating rapid and reliable attainment of therapeutic levels, yet paediatric data are lacking.
Research
Perinatal risk factors associated with skin infection hospitalisation in Western Australian Aboriginal and Non-Aboriginal childrenWe have quantified the relative influence of perinatal risk factors associated with skin infection hospitalisations in WA children
News & Events
The Kids Research Institute Australia leader named finalist in nation’s top science prizesOne of Australia’s leading infectious disease experts, Associate Professor Asha Bowen, has been announced as a finalist for the country’s leading national science awards – the Australian Museum Eureka Prizes.
Research
Impact of an Ivermectin Mass Drug Administration on Scabies Prevalence in a Remote Australian Aboriginal Community.Scabies is endemic in many Aboriginal and Torres Strait Islander communities, with 69% of infants infected in the first year of life.
News & Events
Beating the bugs: a new resource helping to keep skin healthyA year after launching the first National Healthy Skin Guideline to address record rates of skin infections in Australia’s Indigenous communities, The Kids Research Institute Australia has released a new resource as part of the guideline.
News & Events
Port Hedland welcomes health experts from around AustraliaPort Hedland is hosting some of Australia’s most respected health researchers this week as they join forces with local health professionals to improve the health of people living in the tropical north of the country.
Research
Clinic attendances during the first 12 months of life for Aboriginal children in five remote communities of northern AustraliaThe median number of presentations per child in the first year of life was 21 with multiple reasons for presentation.